Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury

There are many published articles on the effects of the antithrombolytic function of platelet glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa inhibitors) in myocardial infarction. However, few studies have explored the effects and optimal concentration of tirofibans in diminishing the extent of myocar...

Full description

Saved in:

Bibliographic Details
Published in:	International Heart Journal Vol. 56; no. 3; pp. 335 - 340
Main Authors:	Chang, Shih-Tai, Chung, Chang-Min, Chu, Chi-Ming, Yang, Teng-Yao, Pan, Kuo-Li, Hsu, Jen-Te, Hsiao, Ju-Feng
Format:	Journal Article
Language:	English
Published:	Japan International Heart Journal Association 2015
Subjects:	Animals Apoptosis Coronary artery disease IIb/IIIa platelet inhibitor In Situ Nick-End Labeling Malondialdehyde - analysis Myocardial Reperfusion Injury - pathology Myocardial Reperfusion Injury - prevention & control Myocardium - chemistry Myocardium - pathology Peroxidase - blood Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Rats Rats, Sprague-Dawley Tyrosine - administration & dosage Tyrosine - analogs & derivatives Tyrosine - pharmacology Tyrosine - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	There are many published articles on the effects of the antithrombolytic function of platelet glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa inhibitors) in myocardial infarction. However, few studies have explored the effects and optimal concentration of tirofibans in diminishing the extent of myocardial reperfusion injury (RI). Rats received 120 minutes of coronary ligation and 180 minutes of reperfusion. The rats were then divided into 7 groups based on the concentration of tirofiban administered intravenously 30 minutes prior to coronary reperfusion to the end of reperfusion. The ratio of myocardial necrotic area to area at risk (AAR), and myocardial malondialdehyde (MDA) and plasma myeloperoxidase (MPO) activities were measured. The apoptotic index (AI) was the percentage of myocytes positive for terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) out of all myocytes stained by 4’, 6-diamidino-2-phenylindole (DAPI). The ratio of myocardial necrotic area to AAR significantly decreased in all tirofiban subgroups. The MDA activity for tirofiban concentrations of 2 and 5 ug/kg/minute showed a slight reduction. MPO activity was significantly decreased at a tirofiban concentration of 2 ug/kg/minute. The AI was significantly decreased at a tirofiban concentration of ≥ 0.4 ug/kg/minute. The results indicate that a tirofiban can significantly ameliorate the cardiac RI and myocyte apoptosis in rats.
AbstractList	There are many published articles on the effects of the antithrombolytic function of platelet glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa inhibitors) in myocardial infarction. However, few studies have explored the effects and optimal concentration of tirofibans in diminishing the extent of myocardial reperfusion injury (RI). Rats received 120 minutes of coronary ligation and 180 minutes of reperfusion. The rats were then divided into 7 groups based on the concentration of tirofiban administered intravenously 30 minutes prior to coronary reperfusion to the end of reperfusion. The ratio of myocardial necrotic area to area at risk (AAR), and myocardial malondialdehyde (MDA) and plasma myeloperoxidase (MPO) activities were measured. The apoptotic index (AI) was the percentage of myocytes positive for terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) out of all myocytes stained by 4’, 6-diamidino-2-phenylindole (DAPI). The ratio of myocardial necrotic area to AAR significantly decreased in all tirofiban subgroups. The MDA activity for tirofiban concentrations of 2 and 5 ug/kg/minute showed a slight reduction. MPO activity was significantly decreased at a tirofiban concentration of 2 ug/kg/minute. The AI was significantly decreased at a tirofiban concentration of ≥ 0.4 ug/kg/minute. The results indicate that a tirofiban can significantly ameliorate the cardiac RI and myocyte apoptosis in rats.
Author	Hsu, Jen-Te Chang, Shih-Tai Chu, Chi-Ming Chung, Chang-Min Pan, Kuo-Li Hsiao, Ju-Feng Yang, Teng-Yao
Author_xml	– sequence: 1 fullname: Chang, Shih-Tai organization: Division of Cardiology, Chiayi Chang Gung Memorial Hospital, Chiayi School, Chang Gung Institute of Technology – sequence: 2 fullname: Chung, Chang-Min organization: Division of Cardiology, Chiayi Chang Gung Memorial Hospital, Chiayi School, Chang Gung Institute of Technology – sequence: 3 fullname: Chu, Chi-Ming organization: Section of Health Informatics, Institute of Public Health, National Defense Medical Center and University – sequence: 4 fullname: Yang, Teng-Yao organization: Division of Cardiology, Chiayi Chang Gung Memorial Hospital, Chiayi School, Chang Gung Institute of Technology – sequence: 5 fullname: Pan, Kuo-Li organization: Division of Cardiology, Chiayi Chang Gung Memorial Hospital, Chiayi School, Chang Gung Institute of Technology – sequence: 6 fullname: Hsu, Jen-Te organization: Division of Cardiology, Chiayi Chang Gung Memorial Hospital, Chiayi School, Chang Gung Institute of Technology – sequence: 7 fullname: Hsiao, Ju-Feng organization: Division of Cardiology, Chiayi Chang Gung Memorial Hospital, Chiayi School, Chang Gung Institute of Technology
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25912900$$D View this record in MEDLINE/PubMed
BookMark	eNo9kMtOwzAQRS1URB-w4QNQ1khp_YgdsqOqoESqBEJlwcqyY5s6SuPIThf9e1xSupm50py5izMFo9a1GoB7BOeIErawu3qOspRgfAUmiGRFjEUxOmdMGB2DaQg1hBmiML8BY0wLhAsIJ-D7oxG9bnSfrJtj5Trvem3bpCzloixLkZTtzkrbO59srXfGStEmy71urPPxLyQr4ZUVVfKpO-3NIVgXn9v64I-34NqIJui7856Br9eX7eot3byvy9Vyk1YU532qMMopzYnBiBCZScEkEwTR3BCqlGKGUpErw1RBlSkqbJ4kohmLmRAMhSIz8Dj0Vt6F4LXhnbd74Y8cQX7yw6MfjjIe_UT4YYC7g9xrdUH_hUTgeQDq0IsffQGE723V6L8uyjg5jaHzcqp2wnPdkl-vU3pw
CitedBy_id	crossref_primary_10_1536_ihj_16_091 crossref_primary_10_3389_fphys_2021_763085 crossref_primary_10_1177_1074248419861437 crossref_primary_10_3892_mmr_2018_8680 crossref_primary_10_3390_ijms25126797 crossref_primary_10_1021_acsnano_9b01798 crossref_primary_10_1016_j_thromres_2024_04_026 crossref_primary_10_1016_j_ejphar_2018_05_014 crossref_primary_10_6061_clinics_2021_e2728 crossref_primary_10_12659_MSM_898015 crossref_primary_10_1177_1535370216647126 crossref_primary_10_1253_circj_CJ_17_0022 crossref_primary_10_1016_j_jnutbio_2022_108975 crossref_primary_10_1021_acsami_3c18402
Cites_doi	10.1097/00003246-200205001-00007 10.1007/s11239-006-9000-0 10.1152/ajpheart.00634.2005 10.1097/00005344-199807000-00024 10.1161/01.CIR.101.3.239 10.1001/jama.293.14.1759 10.1161/01.ATV.20.10.2226 10.1016/S0140-6736(02)07442-1 10.1161/hc4801.100236 10.1177/107602969900500406 10.1097/00005344-199101000-00016 10.1007/s10495-009-0398-7 10.1161/01.CIR.99.21.2720 10.1093/eurheartj/ehl472 10.1161/01.CIR.97.8.795 10.1161/01.CIR.98.24.2695 10.1152/ajpgi.2001.281.6.G1432 10.1016/j.ejphar.2007.04.031 10.1093/eurheartj/ehr236 10.1007/s003950170027 10.1001/jama.297.1.43 10.1152/ajpheart.1991.261.3.H874 10.1189/jlb.72.3.455 10.1016/S1050-1738(00)00029-3 10.1016/S0140-6736(02)11278-5 10.1016/S0735-1097(02)02136-8 10.1093/cvr/28.11.1662 10.1016/j.yjmcc.2009.03.019 10.1161/01.CIR.98.13.1322 10.1161/01.RES.0000137171.97172.d7 10.1038/ncpcardio0096 10.1182/blood.V92.2.507 10.1016/j.jacc.2003.07.017 10.1016/j.jacc.2012.06.004 10.1067/mhj.2001.113574 10.1016/0735-1097(95)00578-1 10.1161/01.CIR.0000087447.12918.85 10.1182/blood.V94.11.3829 10.1161/01.ATV.17.3.528 10.1056/NEJM200106213442503 10.1016/S0008-6363(98)00032-7
ContentType	Journal Article
Copyright	2015 by the International Heart Journal Association
Copyright_xml	– notice: 2015 by the International Heart Journal Association
DBID	CGR CUY CVF ECM EIF NPM AAYXX CITATION
DOI	10.1536/ihj.14-322
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef
DatabaseTitleList	MEDLINE
Database_xml	– sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1349-3299
EndPage	340
ExternalDocumentID	10_1536_ihj_14_322 25912900 article_ihj_56_3_56_14_322_article_char_en
Genre	Journal Article
GroupedDBID	--- .55 29J 2WC 3O- 53G 5GY AAUGY ACPRK ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P GX1 JSF JSH KQ8 OK1 RJT RZJ SDH TKC TR2 X7M ZXP CGR CUY CVF ECM EIF NPM AAYXX CITATION
ID	FETCH-LOGICAL-c527t-d2175573f2133b4ba6b6a3157f35ddd6f55a7df6d95df9c2f8b1546df93320ad3
ISSN	1349-2365
IngestDate	Fri Aug 23 02:37:33 EDT 2024 Sat Sep 18 07:12:04 EDT 2021 Thu Aug 17 20:27:26 EDT 2023
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Language	English
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c527t-d2175573f2133b4ba6b6a3157f35ddd6f55a7df6d95df9c2f8b1546df93320ad3
OpenAccessLink	https://www.jstage.jst.go.jp/article/ihj/56/3/56_14-322/_article/-char/en
PMID	25912900
PageCount	6
ParticipantIDs	crossref_primary_10_1536_ihj_14_322 pubmed_primary_25912900 jstage_primary_article_ihj_56_3_56_14_322_article_char_en
PublicationCentury	2000
PublicationDate	2015
PublicationDateYYYYMMDD	2015-01-01
PublicationDate_xml	– year: 2015 text: 2015
PublicationDecade	2010
PublicationPlace	Japan
PublicationPlace_xml	– name: Japan
PublicationTitle	International Heart Journal
PublicationTitleAlternate	Int. Heart J.
PublicationYear	2015
Publisher	International Heart Journal Association
Publisher_xml	– name: International Heart Journal Association
References	29. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-81. 37. Massberg S, Enders G, Leiderer R, et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998; 92: 507-15. 8. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-90. 9. APEX AMI Investigators, Armstrong PW, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297: 43-51. 18. Serebruany VL, Yurovsky VV, Gurbel PA. Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine. Clin Appl Thromb Hemost 1999; 5: 236-42. 6. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 2002; 30: S214-9. (Review) 25. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000; 101: 239-43. 38. Salter JW, Krieglstein CF, Issekutz AC, Granger DN. Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1432-9. 1. Yellon DM, Baxter GF. Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 1999; 9: 245-9. (Review) 17. Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 290: H692-9. 33. Song JQ, Teng X, Cai Y, Tang CS, Qi YF. Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1-53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis 2009; 14: 1299-307. 43. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47: 32-40. (Review) 24. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-701. 31. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998; 97: 795-804. 35. Kupatt C, Habazettl H, Hanusch P, et al. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol 2000; 20: 2226-32. 42. Hohlfeld T, Strobach H, Schrör K. Stimulation of prostacyclin synthesis by defibrotide: improved contractile recovery from myocardial “stunning.” J Cardiovasc Pharmacol 1991; 17: 108-15. 19. Lefer AM, Campbell B, Scalia R, Lefer DJ. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. Circulation 1998; 98: 1322-8. 14. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients’ data with long-term follow-up. Eur Heart J 2007; 28: 443-9. 2. Bolli R, Becker L, Gross G, et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004; 95: 125-34. (Review) 10. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528-35. 32. Arai M, Lefer DJ, So T, DiPaula A, Aversano T, Becker LC. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol 1996; 27: 1278-85. 40. Massberg S, Enders G, Matos FC, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999; 94: 3829-38. 3. Cannon RO 3rd. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2005; 2: 88-94. (Review) 13. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293: 1759-65. 41. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720-32. 20. Heindl B, Zahler S, Welsch U, Becker BF. Disparate effects of adhesion and degranulation of platelets on myocardial and coronary function in postischaemic hearts. Cardiovasc Res 1998; 38: 383-94. 7. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F, HALT-MI Investigators. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40: 1199-204. 22. Flores NA, Goulielmos NV, Seghatchian MJ, Sheridan DJ. Myocardial ischaemia induces platelet activation with adverse electrophysiological and arrhythmogenic effects. Cardiovasc Res 1994; 28: 1662-71. 15. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007; 23: 57-63. (Review) 11. Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360: 1189-96. 28. Hamm CW, Bassand JP, Agewall S, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054. 36. Kupatt C, Wichels R, Horstkotte J, Krombach F, Habazettl H, Boekstegers P. Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion. J Leukoc Biol 2002; 72: 455-61. 16. Jennings RB, Murry CE, Steenbergen C Jr, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation 1990; 82: II2-12. 39. Chintala MS, Bernardino V, Chiu PJ. Cyclic GMP but not cyclic AMP prevents renal platelet accumulation after ischemia-reperfusion in anesthetized rats. J Pharmacol Exp Ther 1994; 271: 1203-8. 5. Gonon AT, Gourine AV, Middelveld RJ, Alving K, Pernow J. Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion. Basic Res Cardiol 2001; 96: 454-62. 34. Fu J, Huang H, Liu J, Pi R, Chen J, Liu P. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 2007; 568: 213-21. 26. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879-85. 4. Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001; 104: 2778-83. 27. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98. 21. Seligmann C, Kupatt C, Becker BF, Zahler S, Beblo S. Adenosine endogenously released during early reperfusion mitigates postischemic myocardial dysfunction by inhibiting platelet adhesion. J Cardiovasc Pharmacol 1998; 32: 156-63. 23. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903. 12. de Lemos JA, Gibson CM, Antman EM, et al. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. Am Heart J 2001; 141: 592-8. 30. Viehman GE, Ma XL, Lefer DJ, Lefer AM. Time course of endothelial dysfunction and myocardial injury during coronary arterial occlusion. Am J Physio 1991; 261: H874-81 22 23 24 25 26 27 28 29 30 31 10 32 11 33 12 34 13 35 14 36 15 37 16 38 17 39 18 19 1 2 3 4 5 6 7 8 9 40 41 20 42 21 43
References_xml	– ident: 6 doi: 10.1097/00003246-200205001-00007 – ident: 39 – ident: 15 doi: 10.1007/s11239-006-9000-0 – ident: 17 doi: 10.1152/ajpheart.00634.2005 – ident: 21 doi: 10.1097/00005344-199807000-00024 – ident: 25 doi: 10.1161/01.CIR.101.3.239 – ident: 16 – ident: 13 doi: 10.1001/jama.293.14.1759 – ident: 35 doi: 10.1161/01.ATV.20.10.2226 – ident: 27 doi: 10.1016/S0140-6736(02)07442-1 – ident: 4 doi: 10.1161/hc4801.100236 – ident: 18 doi: 10.1177/107602969900500406 – ident: 42 doi: 10.1097/00005344-199101000-00016 – ident: 33 doi: 10.1007/s10495-009-0398-7 – ident: 41 doi: 10.1161/01.CIR.99.21.2720 – ident: 14 doi: 10.1093/eurheartj/ehl472 – ident: 31 doi: 10.1161/01.CIR.97.8.795 – ident: 24 doi: 10.1161/01.CIR.98.24.2695 – ident: 38 doi: 10.1152/ajpgi.2001.281.6.G1432 – ident: 34 doi: 10.1016/j.ejphar.2007.04.031 – ident: 28 doi: 10.1093/eurheartj/ehr236 – ident: 5 doi: 10.1007/s003950170027 – ident: 9 doi: 10.1001/jama.297.1.43 – ident: 30 doi: 10.1152/ajpheart.1991.261.3.H874 – ident: 36 doi: 10.1189/jlb.72.3.455 – ident: 1 doi: 10.1016/S1050-1738(00)00029-3 – ident: 11 doi: 10.1016/S0140-6736(02)11278-5 – ident: 7 doi: 10.1016/S0735-1097(02)02136-8 – ident: 22 doi: 10.1093/cvr/28.11.1662 – ident: 43 doi: 10.1016/j.yjmcc.2009.03.019 – ident: 19 doi: 10.1161/01.CIR.98.13.1322 – ident: 2 doi: 10.1161/01.RES.0000137171.97172.d7 – ident: 3 doi: 10.1038/ncpcardio0096 – ident: 37 doi: 10.1182/blood.V92.2.507 – ident: 26 doi: 10.1016/j.jacc.2003.07.017 – ident: 29 doi: 10.1016/j.jacc.2012.06.004 – ident: 12 doi: 10.1067/mhj.2001.113574 – ident: 32 doi: 10.1016/0735-1097(95)00578-1 – ident: 8 doi: 10.1161/01.CIR.0000087447.12918.85 – ident: 40 doi: 10.1182/blood.V94.11.3829 – ident: 10 doi: 10.1161/01.ATV.17.3.528 – ident: 23 doi: 10.1056/NEJM200106213442503 – ident: 20 doi: 10.1016/S0008-6363(98)00032-7
SSID	ssj0041507
Score	2.1594644
Snippet	There are many published articles on the effects of the antithrombolytic function of platelet glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa inhibitors) in...
SourceID	crossref pubmed jstage
SourceType	Aggregation Database Index Database Publisher
StartPage	335
SubjectTerms	Animals Apoptosis Coronary artery disease IIb/IIIa platelet inhibitor In Situ Nick-End Labeling Malondialdehyde - analysis Myocardial Reperfusion Injury - pathology Myocardial Reperfusion Injury - prevention & control Myocardium - chemistry Myocardium - pathology Peroxidase - blood Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Rats Rats, Sprague-Dawley Tyrosine - administration & dosage Tyrosine - analogs & derivatives Tyrosine - pharmacology Tyrosine - therapeutic use
Title	Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury
URI	https://www.jstage.jst.go.jp/article/ihj/56/3/56_14-322/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/25912900
Volume	56
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
ispartofPNX	International Heart Journal, 2015, Vol.56(3), pp.335-340
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dixMxEA-9U8QX8dv6RUDfjnjbZJPtPh696i1SEazgPS352Ng96vao1wf_eycf-1EO4UR8Ccskm2xnfpnMTJMMQm9TKystckbAnFcklSohKs8lESYTXPFEaeNDF1-yT9-mp_N0Phq12Vt72n-VNNBA1u7k7F9Iu-sUCPAMMocSpA7ljeT-eQ3WIwjj6MP6l974axjq5qgoFHRZFIUEjbCqFczjLcjJJexWMMNPflRrd1bfBWFnHjNue_1ltbU7F02Ddy52-2en9yOJZ8DF7q_twY6BGIte1SuylHVfETWMb0EWdTOoCfTaUb93Kil2tKyg-bncDEMV4ZhmcFz__E3XYBj0MEtzQllII_Gu6mmMhnxKrfIOt5JHkLKBJmaMDxZ1Fu6EurZecJ_Qpl65FQP6pv2q2O1VjJIsoVHJRclcMUlLaFy2Ve6AHGDvAN2ioO5cHo3T4mNrD6TO5PZuf_xJ8ZJcGPq4H3jPLLp9AZ6Bu_Jhz9PxFs_yProXOYdPwvAP0KhqHqI7i7gZ4xE6b6GGh1DDALVjBzTcAQ13QMMDoOEINDwAGg5Ae4y-vp8vZ2ckZuogmtPsihhwbDnPmKUTxlSqpFBCsgnPLOPGGGE5l5mxwuTc2FxTO1Vgugt4Zowm0rAn6LDZNNUzhBU1VnOubZVMU6ttbrTiUy1SPjEZDDJGb1pGlZfhQpbSObLATi-iIJoxygMPuzY3F-MYPQ1s796lPHfh2uT5P_T6At11UyJE716iw6vtrnqFDn6a3WsPFyjns8Vvq5mrcw
link.rule.ids	315,782,786,4028,27932,27933,27934
linkProvider	Flying Publisher
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Platelet+Glycoprotein+IIb%2FIIIa+Inhibitor+Tirofiban+Ameliorates+Cardiac+Reperfusion+Injury&rft.jtitle=International+Heart+Journal&rft.au=Chang%2C+Shih-Tai&rft.au=Chung%2C+Chang-Min&rft.au=Chu%2C+Chi-Ming&rft.au=Yang%2C+Teng-Yao&rft.date=2015&rft.pub=International+Heart+Journal+Association&rft.issn=1349-2365&rft.eissn=1349-3299&rft.volume=56&rft.issue=3&rft.spage=335&rft.epage=340&rft_id=info:doi/10.1536%2Fihj.14-322&rft.externalDocID=article_ihj_56_3_56_14_322_article_char_en
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1349-2365&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1349-2365&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1349-2365&client=summon